Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$78.36 - $124.66 $744,420 - $1.18 Million
-9,500 Reduced 34.67%
17,900 $2.13 Million
Q2 2024

Aug 14, 2024

BUY
$80.36 - $102.87 $1.07 Million - $1.37 Million
13,300 Added 94.33%
27,400 $2.2 Million
Q1 2024

May 15, 2024

SELL
$88.96 - $112.35 $7.61 Million - $9.61 Million
-85,500 Reduced 85.84%
14,100 $1.3 Million
Q4 2023

Feb 14, 2024

BUY
$90.91 - $112.75 $5.76 Million - $7.15 Million
63,400 Added 175.14%
99,600 $10.5 Million
Q3 2023

Nov 14, 2023

SELL
$98.5 - $125.08 $866,800 - $1.1 Million
-8,800 Reduced 19.56%
36,200 $3.93 Million
Q2 2023

Aug 14, 2023

BUY
$102.58 - $129.66 $3.5 Million - $4.42 Million
34,100 Added 312.84%
45,000 $4.86 Million
Q1 2023

May 15, 2023

SELL
$122.57 - $153.67 $3.08 Million - $3.86 Million
-25,100 Reduced 69.72%
10,900 $1.36 Million
Q4 2022

Feb 14, 2023

BUY
$118.43 - $186.05 $1.56 Million - $2.46 Million
13,200 Added 57.89%
36,000 $5.41 Million
Q3 2022

Nov 14, 2022

SELL
$127.65 - $183.11 $382,950 - $549,330
-3,000 Reduced 11.63%
22,800 $3.08 Million
Q2 2022

Aug 08, 2022

SELL
$123.25 - $186.24 $3.96 Million - $5.98 Million
-32,100 Reduced 55.44%
25,800 $3.85 Million
Q1 2022

May 16, 2022

BUY
$126.25 - $231.85 $5.92 Million - $10.9 Million
46,900 Added 426.36%
57,900 $9.88 Million
Q4 2021

Feb 14, 2022

BUY
$216.64 - $362.52 $454,944 - $761,292
2,100 Added 23.6%
11,000 $2.84 Million
Q3 2021

Nov 15, 2021

SELL
$205.93 - $447.23 $494,232 - $1.07 Million
-2,400 Reduced 21.24%
8,900 $2.43 Million
Q2 2021

Aug 16, 2021

BUY
$113.32 - $241.49 $691,252 - $1.47 Million
6,100 Added 117.31%
11,300 $2.53 Million
Q1 2021

May 17, 2021

BUY
$85.73 - $119.5 $145,741 - $203,150
1,700 Added 48.57%
5,200 $568,000
Q4 2020

Feb 16, 2021

BUY
$72.71 - $129.54 $254,484 - $453,390
3,500 New
3,500 $285,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $24.2B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.